Effect of Intravenous Adipose Tissue-Derived Mesenchymal Stem Cell Administration on Glycemic Index in a Cat with Diabetes Mellitus

Yıl 2025, Cilt: 15 Sayı: 2, 343 - 351, 25.12.2025

Yasin Parlatır , İbrahim Süner , Burak Antakyalıoğlu , Mümin Alper Erdoğan

https://doi.org/10.53518/mjavl.1665638

Öz

Diabetes mellitus is caused by the defect of the insulin mechanism and characterised by hyperglycemia. Diabetes mellitus is a common disease in humans and is seen in dogs and cats. The disease pathophysiology is the same as that of humans. For this reason, diabetes mellitus in dogs and cats is classified according to medical literature. There is not a certain treatment method for diabetes mellitus. Management of the disease is based on keeping blood glucose within normal limits. Different methods are applied to keep the glycemic index between reference parameters. In recent years, it has been reported that stem cell applications have the ability to regenerate pancreatic beta cells and that stem cell applications can be used in diabetes mellitus cases. Adipose tissue-derived mesenchymal stem cells are used in veterinary medicine as safe and non-complicated applications. When studies on humans and stem cells accessible in veterinary medicine are evaluated, adipose tissue-derived mesenchymal stem cells come to the fore in cases of diabetes. In this case report, we avaluated the results of stem cell application along with insulin and diet in controlling the glycemic index in a cat diagnosed with diabetes. In this case, no side effects were observed, and similar results were obtained with studies conducted on insulin and diet. As a result of this case, the existence of a larger number of patients was emphasized, and the potential reported features of stem cell applications in diabetes cases were emphasized.

Anahtar Kelimeler

Diabetes Mellitus , Cat , Mezenşimal , Stem Cells

Etik Beyan

This case report was constituted with an informed consent form obtained from the cat’s owner.

Diabetes Mellituslu Bir Kedide ntravenöz Yağ Doku Kökenli Mezenşimal Kök Hücre Uygulamasının Glisemik İndeks Üzerine Olan Etkisi

Öz

Diabetes mellitus, hiperglisemi ile seyreden, organizmadaki insulin mekanizmasının fonksiyon kaybından kaynaklanan bir hastalıktır. İnsanlarda yoğun olarak görüldüğü gibi kedi ve köpeklerde de görülmektedir. Patofizyolojisi insanlardakine benzemektedir. Bu sebeple kedi ve köpeklerdeki diabet olguları insanlardakine benzer şekilde sınıflandırılır. Diabetin kesin bir tedavisi bulunmamaktadır. Hastalığın yönetimi kan glukoz düzeyinin normal sınırlarda tutulmasına dayalıdır. Glisemik endeksi normal sınırlarda tutabilmek için farklı metotlar uygulanmaktadır. Son yıllarda yapılan çalışmalarda, kök hücre uygulamalarının bu yönde kullanılabileceği ve kök hücre uygulamalarının pankreas beta hücreleri üzerinde rejenerasyon kabiliyetinin olduğu bildirilmektedir. Yağ doku kökenli mezenşimal kök hücreler veteriner hekimlikte güvenli ve komplikasyona neden olmayan uygulamalar olarak yer almaktadır. İnsanlarda yapılan çalışmalar ve veteriner hekimlikte ulaşılabilen kök hücreler değerlendirildiğinde yağ doku kökenli mezenşimal kök hücreler diabet olgularında öne çıkmaktadır. Bu olgu sunumunda diabet tanısı koyulmuş bir kedide, glisemik indeksin kontrol altına alınmasında; insulin ve diyetin yanında kök hücre uygulamasının sonuçları değerlendirilmiştir. Bu vakada herhangi bir yan etki görülmediği gibi insulin ve diyet uygulanarak yapılan çalışmalar ile benzer sonuçlar elde edilmiştir. Bu klinik vaka çalışması sonucunda daha kapsamlı araştırmaların gerekliliği vurgulanarak, kök hücre uygulamalarının diabet olgularında potansiyel faydalar taşıdığı kanaatine varılmıştır.

Anahtar Kelimeler

Diabetes Mellitus , Kedi , Mezenşimal , Kök Hücre

Etik Beyan

Bu vaka raporu, kedinin sahibinden alınan bilgilendirilmiş onam formu ile oluşturulmuştur.

Kaynakça

• Ackerman, N., Benchekroun, G., Bourne, D., Caney, S., Cannon, M., Daminet, S., Davison, L., Dunning, M., Fleeman, L., Smith-Fleming, E., Herrtage, M., Mooney, C.T., Niessen, S. & Petrie, G. (2018). Diabetes mellitus: Guidance for managing diabetes in practice. Companion animal, 23(3), 143-151. https://doi.org/10.12968/coan.2018.23.3.143.
• Baral, R.M., Rand, J.S., Catt, M.J. & Farrow H.A. (2003). Prevalence of feline diabetes mellitus in a feline private practice. ACVIM. 21st Annual ACVIM Forum, North Carolina, USA.
• Chhabra, P., & Brayman, K. L. (2013). Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem cells translational medicine, 2(5), 328-336. https://doi.org/10.5966/sctm.2012-0116
• Dang, L. T. T., Phan, N. K., & Truong, K. D. (2017). Mesenchymal stem cells for diabetes mellitus treatment: new advances. Biomedical Research and Therapy, 4(1), 1062-1081. https://doi.org/10.15419/bmrat.v4i1.144.
• Fadini, G. P., Sartore, S., Albiero, M., Baesso, I., Murphy, E., Menegolo, M., Grego, F., Kreutzenberg, S.V.,Tiengo A., Agostini, C. & Avogaro, A. (2006). Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arteriosclerosis, thrombosis, and vascular biology, 26(9), 2140-2146. https://doi.org/10.1161/01.ATV.0000237750.44469.88
• Gaba, R. C., Garcia-Roca, R., & Oberholzer, J. (2012). Pancreatic islet cell transplantation: an update for interventional radiologists. Journal of Vascular and Interventional Radiology, 23(5), 583-594. https://doi.org/10.1016/j.jvir.2012.01.057
• Georgia, S., & Bhushan, A. (2004). β cell replication is the primary mechanism for maintaining postnatal β cell mass. The Journal of clinical investigation, 114(7), 963-968. https://doi.org/ 10.1172/JCI22098
• Gottlieb, S., Rand, J. S., Marshall, R., & Morton, J. (2015). Glycemic status and predictors of relapse for diabetic cats in remission. Journal of Veterinary Internal Medicine, 29(1), 184-192. https://doi.org/10.1111/jvim.12509.
• Hess, D., Li, L., Martin, M., Sakano, S., Hill, D., Strutt, B. Thyssen, S., Gray, D.A. & Bhatia, M. (2003). Bone marrow– derived stem cells initiate pancreatic regeneration. Nature biotechnology, 21(7), 763-770. https://doi.org/10.1038/nbt841
• Hussain, M. A., & Theise, N. D. (2004). Stem-cell therapy for diabetes mellitus. The Lancet, 364(9429), 203- 205. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16635-X/fulltext
• Kruth, S., Cowgill, L. (1982). Renal Glucose transport in the cat (Abstract). [In:] American College Of Veterinary Internal Medicine Forum 78.
• Link, K. R., & Rand, J. S. (2008). Changes in blood glucose concentration are associated with relatively rapid changes in circulating fructosamine concentrations in cats. Journal of feline medicine and surgery, 10(6), 583-592. https://doi.org/10.1016/j.jfms.2008.08.005
• Marshall, R. D., Rand, J. S., & Morton, J. M. (2009). Treatment of newly diagnosed diabetic cats with glargine insulin improves glycaemic control and results in higher probability of remission than protamine zinc and lente insulins. Journal of feline medicine and surgery, 11(8), 683-691. https://doi.org/10.1016/j.jfms.2009.05.016
• McCann, T. M., Simpson, K. E., Shaw, D. J., Butt, J. A., & Gunn-Moore, D. A. (2007). Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. Journal of Feline Medicine and Surgery, 9(4), 289-299. https://doi.org/10.1016/j.jfms.2007.02.001
• Pera, M. F., & Tam, P. P. (2010). Extrinsic regulation of pluripotent stem cells. Nature, 465(7299), 713-720. https://doi.org/10.1038/nature09228.
• Rand, J. S., Fleeman, L. M., Farrow, H. A., Appleton, D. J., & Lederer, R. (2004). Canine and feline diabetes mellitus: nature or nurture?. The Journal of nutrition, 134(8), 2072S-2080S. https://jn.nutrition.org/article/S0022-3166(23)03003-1/fulltext
• Rand, J. S. (2020). Diabetes Mellitus in Dogs and Cats. In: Bruyette, D. S. (Ed). Clinical Small Animal Internal Medicine Volume I. (pp. 93-102) 1st ed. NJ: Wiley and Sons.
• Rand, J., Gottlieb, S.A. (2000). Feline Diabetes Mellitus. In: Ettinger, S.J., Feldman, E.C. (Ed.). Textbook of Veterinary Internal Medicine. (pp. 4306-4344) 5th ed. Philadelphia: Saunders.
• Reeve-Johnson, M. K., Rand, J. S., Vankan, D., Anderson, S. T., Marshall, R., & Morton, J. M. (2016). Diagnosis of prediabetes in cats: glucose concentration cut points for impaired fasting glucose and impaired glucose tolerance. Domestic Animal Endocrinology, 57, 55-62. https://doi.org/10.1016/j.domaniend.2016.05.008
• Reusch, C. (2010) Feline Diabetes mellitus. In: Ettinger, S., Feldman, E. (Ed.) Textbook Of veterinary internal medicine. (pp. 196-1816). 7th Ed. St Louis: Saunders.
• Reusch, C.E. (2015) Feline diabetes mellitus. In: Feldman, C.E., Nelson, R.W., Reusch, C., Scott-Moncrieff, J.C., & Behrend, E. (Ed.). Canine and feline endocrinology. (pp. 258- 314) 4th ed. Saunders, St Louis, USA.
• Rhew, S. Y., Park, S. M., Li, Q., An, J. H., Chae, H. K., Lee, J. H., Ahn, J.O., Song W.J. & Youn, H. Y. (2021). Efficacy and safety of allogenic canine adipose tissue-derived mesenchymal stem cell therapy for insulin- dependent diabetes mellitus in four dogs: A pilot study. Journal of Veterinary Medical Science, 83(4), 592- 600. https://doi.org/10.1292/jvms.20-0195
• Sallander, M., Eliasson, J., & Hedhammar, Å. (2012). Prevalence and risk factors for the development of diabetes mellitus in Swedish cats. Acta Veterinaria Scandinavica, 54, 1-6. https://doi.org/10.1186/1751-0147- 54-61
• Teramura, Y., & Iwata, H. (2010). Bioartificial pancreas: Microencapsulation and conformal coating of islet of Langerhans. Advanced drug delivery reviews, 62(7-8), 827-840. https://doi.org/10.1016/j.addr.2010.01.005
• Will, S. E., Morini Junior, J. C., Alcâtara, D., Fratini, P., Favaron, P. O., Miglino, M. A., & Assis Neto, A. C. D. (2012). Stem cell therapy to restore pancreatic function in dogs and cats. Brazilian Journal Of Veterinary Pathology, 5(2), 99-105.
• Williams, D. L., & Fred Heath, M. (2006). Prevalence of feline cataract: results of a cross‐sectional study of 2000 normal animals, 50 cats with diabetes and one hundred cats following dehydrational crises. Veterinary ophthalmology, 9(5), 341-349. https://doi.org/10.1111/j.1463-5224.2006.00497.x
• Xiao, N., Zhao, X., Luo, P., Guo, J., Zhao, Q., Lu, G., & Cheng, L. (2013). Co-transplantation of mesenchymal stromal cells and cord blood cells in treatment of diabetes. Cytotherapy, 15(11), 1374-1384. https://doi.org/10.1016/j.jcyt.2013.06.013
• Zhang, Y., Chen, W., Feng, B., & Cao, H. (2020). The clinical efficacy and safety of stem cell therapy for diabetes mellitus: a systematic review and meta-analysis. Aging and disease, 11(1), 141. http://doi.org/10.14336/AD.2019.0421.